Mark Brown

Mark Brown has a diverse and extensive work experience in the biotech and pharmaceutical industry. Mark started their career as a Research Assistant at UCL from 2010 to 2012. Mark then had an industrial placement at GlaxoSmithKline Pharma GmbH in 2016. After that, Mark worked at Tusk Therapeutics as a Scientist from 2017 to 2018, where they primarily focused on assay development and multicolour flow cytometry.

Following their time at Tusk Therapeutics, Mark joined Black Belt Therapeutics Ltd in 2018 as a Scientist and later became a Senior Scientist. In this role, they managed a team of research associates and was involved in assay development and optimization for various cell lines and human primary cells.

Mark's most recent role is with Achilles Therapeutics plc, where they have held various positions since 2020. Mark started as a Senior Scientist and eventually became a Principal Scientist. In this role, they led a team of Senior Scientists and Research Associates, developed functional assays, and generated Translational Science data packages for clinical trial materials. Additionally, Mark developed analysis pipelines in R for report automation and standardization purposes.

Mark Brown completed their education in a chronological manner. Mark started from 2003 to 2005, where they attended Boston Spa Comprehensive School and obtained their High School degree, focusing on A levels. Following this, from 2005 to 2009, Mark enrolled at Imperial College London and earned their MSci degree in Biology, General. Continuing their education, they pursued a Doctor of Philosophy (Ph.D.) degree in Cancer and Inflammation from 2012 to 2016 at Barts Cancer Institute.